アブストラクト
| Title | 関節リウマチ治療におけるバイオ製剤とJAK阻害薬の将来展望 |
|---|---|
| Subtitle | 総説 |
| Authors | 村松匠, 東野俊洋, 山岡邦宏 |
| Authors (kana) | |
| Organization | 北里大学医学部膠原病・感染内科学 |
| Journal | 日本病院薬剤師会雑誌 |
| Volume | 58 |
| Number | 2 |
| Page | 156-161 |
| Year/Month | 2022 / 2 |
| Article | 報告 |
| Publisher | 日本病院薬剤師会 |
| Abstract | 「はじめに」関節リウマチ(rheumatoid arthritis: 以下, RA)は, 原因不明の関節滑膜炎を主病態とする全身性自己免疫疾患である. 疾患修飾性抗リウマチ薬(disease modifying anti-rheumatic drugs: 以下, DMARDs)として, メトトレキサート(methotrexate: 以下, MTX)を中心とした従来型DMARDsに加え, 生物学的製剤やヤヌスキナーゼ(以下, JAK)阻害薬といった分子標的薬を用いることで, 日常生活にほとんど影響を及ぼさない状況である「寛解」を達成できる疾患となってきた. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) JA Singh, GA Wells, R Christensen et al.:Adverse effects of biologics:a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, 2011, Cd008794(2011).
- 2) H Wadstrom, T Frisell, J Askling:Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice:A Nationwide Cohort Study From Sweden, JAMA Intern Med, 177, 1605-1612(2017).
- 3) KL Winthrop, H Yamanaka, H Valdez et al.:Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis, Arthritis Rheum, 66, 2675-2684(2014).
- 4) Pfizer Inc.:Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ(R)(tofacitinib)in Subjects with Rheumatoid Arthritis(RA). https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing, 2021年9月17日参照
- 5) PE Lipsky, DM van der Heijde, EW St Clair et al.:Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, N Engl J Med, 343, 1594-1602(2000).
残りの22件を表示する
- 6) Y Tanaka, T Takeuchi, E Inoue et al.:Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan:one-year clinical outcomes (RECONFIRM-2), Mod Rheumatol, 18, 146-152(2008).
- 7) T Takeuchi, N Miyasaka, K Inoue et al.:Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis:results from the RISING study, Mod Rheumatol, 19, 478-487(2009).
- 8) L Klareskog, D van der Heijde, JP de Jager et al.:Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial, Lancet, 363, 675-681(2004).
- 9) P Emery, FC Breedveld, S Hall et al.:Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis(COMET):a randomised, double-blind, parallel treatment trial, Lancet, 372, 375-382(2008).
- 10) T Takeuchi, H Yamanaka, N Ishiguro et al.:Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis:the HOPEFUL 1 study, Ann Rheum Dis, 73, 536-543(2014).
- 11) EC Keystone, MC Genovese, L Klareskog et al.:Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy:the GO-FORWARD Study, Ann Rheum Dis, 68, 789-796(2009).
- 12) R Fleischmann, J Vencovsky, RF van Vollenhoven et al.:Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy:the FAST4WARD study, Ann Rheum Dis, 68, 805-811(2009).
- 13) C Gabay, P Emery, R van Vollenhoven et al.:Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis(ADACTA):a randomised, double-blind, controlled phase 4 trial, Lancet, 381, 1541-1550(2013).
- 14) D McCarty, A Robinson:Efficacy and safety of sarilumab in patients with active rheumatoid arthritis, Ther Adv Musculoskelet Dis, 10, 61-67(2018).
- 15) ME Weinblatt, M Schiff, R Valente et al.:Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis:findings of a phase IIIb, multinational, prospective, randomized study, Arthritis Rheum, 65, 28-38(2013).
- 16) T Takeuchi, Y Tanaka, S Soen et al.:Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs(DESIRABLE study):a randomised, double-blind, placebo-controlled phase 3 trial, Ann Rheum Dis, 78, 899-907(2019).
- 17) R Fleischmann, E Mysler, S Hall et al.:Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis(ORAL Strategy):a phase 3b/4, double-blind, head-to-head, randomised controlled trial, Lancet, 390, 457-468(2017).
- 18) PC Taylor, EC Keystone, D van der Heijde et al.:Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis, N Engl J Med, 376, 652-662(2017).
- 19) Y Tanaka, T Takeuchi, S Tanaka et al.:Efficacy and safety of peficitinib(ASP015K)in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs:a randomised, double-blind, placebo-controlled phase III trial(RAJ3), Ann Rheum Dis, 78, 1320-1332(2019).
- 20) T Takeuchi, Y Tanaka, S Tanaka et al.:Efficacy and safety of peficitinib(ASP015K)in patients with rheumatoid arthritis and an inadequate response to methotrexate:results of a phase III randomised, double-blind, placebo-controlled trial(RAJ4)in Japan, Ann Rheum Dis, 78, 1305-1319(2019).
- 21) RM Fleischmann, MC Genovese, JV Enejosa et al.:Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response, Ann Rheum Dis, 78, 1454-1462(2019).
- 22) RM Fleischmann, R Blanco, S Hall et al.:Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response:efficacy and safety in patients with rheumatoid arthritis, Ann Rheum Dis, 80, 432-439(2020).
- 23) B Combe, A Kivitz, Y Tanaka et al.:Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate:a phase III randomised clinical trial, Ann Rheum Dis, 80, 848-858(2021).
- 24) MC Genovese, K Winthrop, Y Tanaka et al.:Thu0202 Integrated Safety Analysis of Filgotinib Treatment for Rheumatoid Arthritis from 7 Clinical Trials, Ann Rheum Dis, 79, 324-325(2020).
- 25) MC Genovese, JS Smolen, T Takeuchi et al.:Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment:an updated integrated safety analysis, The Lancet Rheumatology, 2, e347-e357(2020).
- 26) T Takeuchi, Y Tanaka, S Tanaka et al.:Safety and Effectiveness of Peficitinib(ASP015K)in Patients with Rheumatoid Arthritis:Final Results(32 Months of Mean Peficitinib Treatment)From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan, Rheumatol Ther, 8, 425-442(2021).
- 27) SB Cohen, RF van Vollenhoven, KL Winthrop et al.:Safety profile of upadacitinib in rheumatoid arthritis:integrated analysis from the SELECT phase III clinical programme, Ann Rheum Dis, 80, 304-311(2020).
